Receive our newsletter – data, insights and analysis delivered to you
September 6, 2011

Phase II trial of chemosaturation system shows inconclusive efficacy

Delcath Systems has reported top-line results from the metastatic colorectal (adenocarcinoma) cohort of a Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer, indicating the need for a further trial. Th

By cms admin

Delcath Systems has reported top-line results from the metastatic colorectal (adenocarcinoma) cohort of a Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer, indicating the need for a further trial.

The Delcath chemosaturation system is designed to administer high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.

The multi-arm Phase II study, conducted at the National Cancer Institute in the US, included four patient cohorts: hepatobiliary cancers, and metastatic cancers of neuroendocrine, ocular or cutaneous melanoma, and colorectal origins.

Sixteen patients with late-stage colorectal cancer liver metastases were recruited into the trial.

The safety profile of the chemosaturation system is consistent with that previously reported for the company’s Phase III melanoma trial.

The efficacy signal from this study is inconclusive and thus there is a need to conduct a new Phase II trial in a well-defined metastatic colorectal patient population who are likely to benefit from chemosaturation with percutaneous hepatic perfusion.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

The company will initiate a new Phase II single-arm study in the second half of next year to evaluate the efficacy of the chemosaturation system and its next-generation, high-efficiency filter in patients with colorectal cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management